Details emerge on CHIME and KLAS partnership

Laura Pedulli | | Health Exec | Economics

 

The College of Healthcare Information Management Executives (CHIME) has formalized its partnership agreement with research firm KLAS Enterprises to accelerate industry performance and provide support to health IT leaders.

The partnership originally was announced in October. Under newly disclosed details of the agreement, the organizations will co-develop best practice and benchmarking studies; establish an industry recognition program for the healthcare C-suite; distribute KLAS research briefs for CHIME members and their affiliated associations; and offer discounted KLAS executive services to CHIME members, according to a press release.


"To keep pace with the healthcare industry's rapidly changing environment, our goal is to get critical, timely market data into the hands of our members, so they can make informed decisions and effectively lead their organizations," said CHIME President and CEO Russell P. Branzell, in a statement.

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.